Unlocked is transforming the treatment of metabolic disorders through the power of genetic engineering. By developing targeted probiotic treatments, Unlocked addresses the root causes of conditions such as hyperuricemia, gout, and kidney stones, providing a novel approach that improves patient outcomes without the side effects associated with conventional drugs.

The prevalence and impact of these metabolic disorders highlight the urgent need for Unlocked's innovative treatments. Traditional pharmaceutical interventions come with limitations and adverse effects, underscoring the significance of Unlocked's safer, more effective alternatives. With its lead products, UA158 and OXO16, Unlocked targets the metabolic pathways associated with uric acid and oxalate accumulation, showcasing a promising leap forward in healthcare.

Unlocked's commitment to scientific rigor, patient-first healthcare, and a preventative approach to medicine positions it as a key innovator in the field. The company not only aims to treat diseases but also enhances the quality of life, leading the charge towards a future where individuals can achieve optimal health and well-being.